

Antoine Monsel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11552006/publications.pdf>

Version: 2024-02-01

29
papers

3,111
citations

430874

18
h-index

454955

30
g-index

32
all docs

32
docs citations

32
times ranked

4031
citing authors

#	ARTICLE	IF	CITATIONS
1	Human Mesenchymal Stem Cell Microvesicles for Treatment of <i>Escherichia coli</i> Endotoxin-Induced Acute Lung Injury in Mice. <i>Stem Cells</i> , 2014, 32, 116-125.	3.2	550
2	Therapeutic Effects of Human Mesenchymal Stem Cell-derived Microvesicles in Severe Pneumonia in Mice. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 324-336.	5.6	392
3	Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study. <i>Lancet Respiratory Medicine</i> , 2020, 8, 1121-1131.	10.7	344
4	Personalised mechanical ventilation tailored to lung morphology versus low positive end-expiratory pressure for patients with acute respiratory distress syndrome in France (the LIVE study): a multicentre, single-blind, randomised controlled trial. <i>Lancet Respiratory Medicine</i> , 2019, 7, 870-880.	10.7	202
5	Intermittent Subglottic Secretion Drainage and Ventilator-associated Pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 910-917.	5.6	173
6	Extracorporeal membrane oxygenation network organisation and clinical outcomes during the COVID-19 pandemic in Greater Paris, France: a multicentre cohort study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 851-862.	10.7	163
7	Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID study. <i>Lancet Respiratory Medicine</i> , 2022, 10, 180-190.	10.7	161
8	Mesenchymal stem cell derived secretome and extracellular vesicles for acute lung injury and other inflammatory lung diseases. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 859-871.	3.1	156
9	Mesenchymal Stem Cell Microvesicles Attenuate Acute Lung Injury in Mice Partly Mediated by <i>Ang-1</i> mRNA. <i>Stem Cells</i> , 2017, 35, 1849-1859.	3.2	154
10	Hospital-acquired pneumonia in ICU. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2018, 37, 83-98.	1.4	135
11	Occurrence of Invasive Pulmonary Fungal Infections in Patients with Severe COVID-19 Admitted to the ICU. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 307-317.	5.6	131
12	Cell-based Therapy for Acute Organ Injury. <i>Anesthesiology</i> , 2014, 121, 1099-1121.	2.5	127
13	Mesenchymal Stem Cell-Derived Extracellular Vesicles Decrease Lung Injury in Mice. <i>Journal of Immunology</i> , 2019, 203, 1961-1972.	0.8	81
14	Preclinical efficacy and clinical safety of clinical-grade nebulized allogenic adipose mesenchymal stromal cells-derived extracellular vesicles. <i>Journal of Extracellular Vesicles</i> , 2021, 10, e12134.	12.2	72
15	Study of Bone Marrow and Embryonic Stem Cell-Derived Human Mesenchymal Stem Cells for Treatment of <i>Escherichia coli</i> Endotoxin-Induced Acute Lung Injury in Mice. <i>Stem Cells Translational Medicine</i> , 2015, 4, 832-840.	3.3	56
16	Comparison of 8 versus 15 days of antibiotic therapy for <i>Pseudomonas aeruginosa</i> ventilator-associated pneumonia in adults: a randomized, controlled, open-label trial. <i>Intensive Care Medicine</i> , 2022, 48, 841-849.	8.2	43
17	Adult stem cells for acute lung injury: Remaining questions and concerns. <i>Respirology</i> , 2013, 18, 744-756.	2.3	38
18	Brief summary of French guidelines for the prevention, diagnosis and treatment of hospital-acquired pneumonia in ICU. <i>Annals of Intensive Care</i> , 2018, 8, 104.	4.6	32

#	ARTICLE	IF	CITATIONS
19	Modification of Tracheal Cuff Shape and Continuous Cuff Pressure Control to Prevent Microaspiration in an Ex Vivo Pig Tracheal Two-Lung Model. <i>Critical Care Medicine</i> , 2017, 45, e1262-e1269.	0.9	13
20	Nebulized antibiotics for ventilator-associated pneumonia: methodological framework for future multicenter randomized controlled trials. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 156-168.	3.1	13
21	Role of miR-466 in mesenchymal stromal cell derived extracellular vesicles treating inoculation pneumonia caused by multidrug-resistant <i>Pseudomonas aeruginosa</i> . <i>Clinical and Translational Medicine</i> , 2021, 11, e287.	4.0	12
22	The IASIS, INHALE and VAPORISE trials. Reasons for a triple failure: Study design, aminoglycosides dosing and technique of nebulisation. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2020, 39, 179-183.	1.4	11
23	Occurrence of Candidemia in Patients with COVID-19 Admitted to Five ICUs in France. <i>Journal of Fungi (Basel, Switzerland)</i> , 2022, 8, 678.	3.5	11
24	Inoculation Pneumonia Caused by Coagulase Negative Staphylococcus. <i>Frontiers in Microbiology</i> , 2019, 10, 2198.	3.5	8
25	Design and Rationale of the Sevoflurane for Sedation in Acute Respiratory Distress Syndrome (SESAR) Randomized Controlled Trial. <i>Journal of Clinical Medicine</i> , 2022, 11, 2796.	2.4	8
26	A small step for sedation that may become a giant leap for critical care medicine. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2019, 38, 425-427.	1.4	5
27	Intraoperative pulmonary hyperdistention estimated by transthoracic lung ultrasound: A pilot study. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2020, 39, 825-831.	1.4	5
28	Personalised mechanical ventilation in acute respiratory distress syndrome: the right idea with the wrong tools? – Authors' reply. <i>Lancet Respiratory Medicine</i> , 2019, 7, e39.	10.7	3
29	One-year patient outcomes based on lung morphology in acute respiratory distress syndrome: secondary analysis of LIVE trial. <i>Critical Care</i> , 2022, 26, .	5.8	2